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ABSTRACT 
Atherogenesis is a multicellular event. Early reports concentrated on the role of endotheliocytes, monocyte - 
macrophages and smooth muscle cells. Recognition of the immuno-inflammatory nature of the process, 
however, expanded the scope of cellular involvement and more recent reviews emphasize the role of immune 
and inflammatory cells. In addition, recent studies reveal that other cells are also involved. Elucidation of all 
the types of cells involved is valuable to inform therapeutic interventions for this disease, but most accounts 
concentrate on cells which are the target of the study and may fail to include other cells. This review therefore 
aimed at consolidating information on the various cells involved in atherogenesis. Review of contemporary 
literature was done for cells in the vessel wall and in blood to check for their potential role in atherogenesis. 
It has been shown that atherogenesis involves all the cells present in the various coats of the vessel wall – 
endotheliocytes, smooth muscle cells, fibroblasts, stem cells, pericytes, mast cells, dendritic cells, 
macrophages and immigrant cells usually found in blood, namely monocytes, neutrophils, lymphocytes, 
platelets and red blood cells. These cells promote atherogenesis by secreting several products which influence 
inflammation, migration, proliferation and secretory activity of each other in a manner that synergises their 
activities. Therapeutic interventions should target the various cell types. 
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INTRODUCTION 
Knowledge of the cells involved in atherogenesis 
is valuable in understanding the pathobiology of 
and the therapeutic approaches in management 
of atherosclerosis. Previous models depicted 
atherosclerosis as an inert lipid handling disorder 
which merely involved endotheliocytes, smooth 
muscle cells and monocyte / macrophages. 
Recognition of inflammatory nature of this 
disease (Packard and Libby, 2008; Libby et al., 
2009; Libby, 2012) increased the scope of cells 
involved. The classical view advanced was that 
the process involves three cellular components 
in circulation – monocytes, T lymphocytes and 
platelets; together with two cells of the arterial 
wall namely endothelial and smooth muscle cells. 
Further analysis expanded the repertoire of cells 
to include most known inflammatory and 
immune cells – monocytes, macrophages, 
dendritic cells, neutrophils, various categories of 
lymphocytes and mast cells (Hanson and Libby, 
2006; Spagnoli et al., 2007; Galkina and Ley, 
2007; Libby et al., 2011; Libby, 2012). There are 
several recent excellent reviews on cellular and 
molecular mechanisms which underly this 
immunoinflammatory process of atherosclerosis 
(Gomez – Guerrero et al., 2012; Wong et al., 
2012; Ilhan and Kalkanli, 2015). Indeed, 
experimental studies on these cellular 
mechanisms continue to reveal potential for their 
successful application in development of drugs 
to mitigate initiation, progression and 
complications of atherosclerosis (Tabas et al., 
2015; Ivanova and Orekhov, 2016). Most of 
these reviews, however, focus on specific cells 
which constitute the therapeutic targets under 
study and often do not cover all cells. As 
atherosclerosis continues to be a major health 
challenge worldwide, there is need for accounts 
that include as many cells as possible in this 
process. This review, therefore, aimed at 
consolidating available knowledge on the types 
of cells involved in atherogenesis.
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Articles were retrieved from Google search using 
the following combinations of key words – cells, 
atherosclerosis; cells, atherogenesis; cellular 
involvement, atherogenesis; inflammation, 
atherosclerosis. Original articles on human, 
animal, experimental studies and several 
classical review papers were reviewed. Special 
emphasis was put on articles published between 
2006 and 2016. Only those papers in which the 
role of the cells was explicit were included. Many 
papers were excluded for lack of clarity, being 
too old, and not being explicit. 
 
FINDINGS  
A total of 13 main cell types were involved in the 
process of atherogenesis. The cells comprised 
those which are usual constituents of the vessel 
wall and formed elements of normal blood. 
These are highlighted below.  
a. The endothelial cells: Previously 
considered to be an inert, semi – permeable 
barrier between blood and the vascular wall, the 
endothelium is now known to be critical in 
maintenance of vascular homeostasis. When 
activated/injured, it exhibits pro inflammatory, 
oxidant, proliferative, procoagulative and pro-
adhesive features which trigger and promote 
atherosclerosis (Chhabra, 2009; Mudau et al., 
2012; Tabas et al., 2015). The role of the 
endothelium in atherosclerosis is through 
production of endothelin and angiotensin II 
which promote proliferation of smooth muscle 
cells and thereby contribute to the formation of 
plaque (Mehta and Grendling, 2007; Suen et al., 
2011; Kohan et al., 2011). Damage to the 
endothelium initiates endothelial permeability, 
platelet aggregation, leukocyte adhesion and 
generation of cytokines which promote or 
exacerbate atherosclerosis. Activation of 
endothelial cells at atherosclerotic lesion prone 
sites causes upregulation of cell adhesion 
molecules and cytokines which mediate 
recruitment of circulating monocytes whose 
accumulation leads to chronic inflammation, 
development and progression of atherosclerosis 
(Mestas and Ley, 2008; Ley et al., 2011; Ghattas 
et al., 2013; Vitiello et al., 2014). 
b. Vascular smooth muscle cells: Vascular 
smooth muscle cells (VSMC) migrate from the 
media to intima, where they proliferate and form 
a neointima with increased extracellular matrix 
(ECM) formation leading to development of an 
organized atherosclerotic plaque. These VSMC 
changes are thought to constitute a late event in 
atherosclerotic process (Rudijanto, 2007). VSMC 
may take on a “proinflammatory” phenotype 
whereby they secrete cytokines and express cell 
adhesion molecules like 1L – 8; 1L- 6 and VCAM 
– 1 which functionally regulate monocyte and 
macrophage adhesion and other processes 
during atherosclerosis (Orr et al., 2010; 
Christiakov et al., 2015). Further, VSMC actively 
mediate inflammation through their regulation of 
cytokine secretion and membrane receptors (Lim 
and Park, 2014). Genetic studies have revealed 
that VSMC switching results in less differentiated 
forms that lack VSMC markers including 
macrophage – like cells which promotes 
atherosclerosis (Bennett et al., 2016) 
c.  Monocytes: Monocytes are attracted to and 
adhere to the dysfunctional endothelium, 
migrate to the subendothelial zone (SEZ) where 
they transform into inflamatory macrophages 
and dendritic cells. These three cells play critical 
roles in initiation and progression of 
atherosclerosis (Ley et al., 2011). Two types of 
monocytes exist: the proinflammatory and the 
less inflammatory one. The inflammatory one 
expresses high level of toll-like receptors (TLR) 
and elaborate cytokines such as tumor necrotic 
factor (TNF) and interleukin (IL)-1. They also 
produce proinflammatory cytokines, reactive 
oxygen species, macrophage mediators 
including matrix metalloproteinases, peroxides, 
chemokines, adhesion molecules and growth 
factors (Libby et al., 2008; Pamukcu et al., 
2010). The less inflammatory ones express 
higher levels of transforming growth factors beta 
(TGF-β), scavengers receptor (CD 36), 
scavenger receptor A (SR-A) and angiogenesis 
mediators including vascular endothelial growth 
factor (VEGF) [Libby et al., 2009]. Monocytes 
therefore play a major role in initiation, 
propagation and progression of atherosclerosis 







from a stable to unstable state (Ghattas et al., 
2013). 
d. Macrophages: Macrophages play diverse 
roles in atherogenesis. They modulate lipid 
metabolism and secrete cytokines, reactive 
oxygen and nitrogen species that drive 
atherogenesis. They also produce proteases and 
tissue factors that contribute to plaque rupture 
and thrombosis (Wilson, 2010; Stoger et al., 
2010). They function as scavenger cells and 
immune mediators (Gui et al., 2012). Cholesterol 
loaded macrophages are a characteristic feature 
of plaques and major players in all stages of 
plaque development. They participate in a mal – 
adaptive, unrelenting inflammation leading to 
further cellular infiltration, lipid and ECM 
accumulation in the SEZ (Moore and Tabas, 
2011). Upon internalization of oxidized low-
density lipoprotein (Ox – LDL), they transform 
into foam cells whose accumulation in the 
arterial wall initiates formation of fatty streaks 
that subsequently develop into advanced 
plaques (Michael et al., 2012). The chemokines 
promote migration of monocyte into the tunica 
intima. Monocyte chemoattractant protein-1 
(MCP-I) attracts monocytes. Macrophage also 
express cyclooxygenose - 2, a key enzyme in 
inflammation which promotes atherosclerotic 
lesion formation (Tabas et al., 2015). Two types 
of macrophages exist in atherosclerotic plaques-
inflammatory (M1) and anti-inflammatory (M2). 
The M1 predominates in disease progression and 
M2 in regression (Peled and Fisher, 2014). A 
distinct non – foam macrophage termed M (Hb) 
promotes plaque neoangiogenesis and 
microvessel via a non – lipid driven mechanism 
– the a HIF – Iα/VEGF – A- dependent pathway 
(Finn et al., 2016). By virtue of their versatility 
and plasticity, macrophages are able to promote 
a series of pathogenic functions ranging from 
release of cytokines, enzymes, reactive oxygen 
species, presentation of antigens and secretion 
of tissue remodeling factors (Shirai et al., 2015).  
e. Platelets: Platelets are involved in the 
initiation, development and total extent of 
atherosclerotic lesions (Lindemann et al., 2007) 
by binding to leucoytes and endothelial cells, and 
initiating monocyte transformation into 
macrophages. They also facilitate the 
recruitment of inflammatory cells towards the 
lesion sites and release various inflammatory 
mediators. The molecules present on the platelet 
surface and /or stored in platelet granules such 
P – Selectin, chemokines and inflammatory 
cytokines; PDGF Platelet factor 4 (PF - 4) 
RANTES: IL – 8 and MCP – 1 contribute to the 
cross – talk of platelets with the inflammatory 
cells in the development and progression of 
atherosclerosis (Davi and Patrono, 2007).  This 
cross – talk among platelets, endothelial cells 
and leucocytes establishes a localized 
inflammatory response that accelerates 
atherosclerosis (Kaplan and Jackson, 2011). 
They also enforce leukocyte activation, adhesion 
and transmigration (Lievens and 
Hundelshausen, 2011). Further, they participate 
in atherogenesis by  releasing chemokines, 
surface association with Ox – LDL, direct cell – 
cell interaction, release of microparticles, pro – 
inflammatory IL – IB, and recruitment of 
leucocytes (Nording et al., 2015).  
f. Lymphocytes: Lymphocytes play an 
important role in early atherogenesis. Circulating 
T-cells migrate into the atherosclerotic lesions in 
response to chemo attractants which bind to the 
cell specific receptors. Within the plaque, various 
antigens such as MLp induce further T-cell 
proliferation (Packard et al., 2009). Further, the 
T cells respond to inflammatory signals by 
orchestrating the production of IFN – Y and TNF 
–β which stimulate monocyte/macrophages, 
dendtric cells (DC), endothelium and SMC to 
perpetuate the inflammatory response in 
atherosclerosis (Libby, 2012; Profumo et al., 
2012). B cells direct the immune response during 
the development of the atherosclerotic plaque 
(Galkina and Ley, 2009). Both T and B 
lymphocytes, as components of adaptive 
immune system, modulate different 
immunopathogenic mechanisms in 
atherosclerosis (Ketelhuth and Hanson, 2014). 
There are multiple potential pathways by which 
B cells can promote atherosclerosis, for example 
by producing cytokines and directly regulating T 
cell responses (Sage and Mallat, 2014). Other 
mechanisms by which lymphocytes influence 







atherogenesis include their cross-talk with 
myeloid cells (Hedrick, 2015) 
g. Dendritic cells: Mature DCs accumulate 
during atheroprogression, cluster with T cells 
(Galkina et al., 2006; Weber et al., 2008; 2011) 
and present antigens such as ox - LDL to naive 
T cells (Packard et al., 2008). They express 
major histocompatibility complex I and II, 
human leucoyte antigen – DR, CDla, intercellular 
adhesion molecule 1, vascular cell adhesion 
molecule – 1 and co – stimulatory molecule on 
their surfaces which activate naïve T cells. 
Activation of T cells leads to release of cytokines 
which are important in disease progression 
(Sharma, 2006; Ranjit and Dazhu, 2006). They 
contribute to early foam cell formation, regulate 
lipid uptake and metabolism (Alberts – Grill et 
al., 2013; Zernecke, 2015) and participate in all 
stages of atherosclerosis from fatty streaks to 
mature lesions (Koltsova and Ley, 2011; 
Bobryshev et al., 2013) mainly by modulating 
adaptive immune responses (Alberts – Grill et al., 
2013; Zernecke, 2015). 
h. Neutrophils: Neutrophils are induced by Ox 
- LDL to transmigrate into SEZ and release 
reactive oxygen species and granule proteins 
such as myeloperoxidase, azurocidin, proteinase 
– 3, cathepsin G, α-defensins, neutrophil 
elastase, proteinase – 3 which in turn trigger 
monocyte recruitment through the various “find- 
me and eat me” signals They trigger a chronic 
inflammatory response that sustains 
atherogenesis (Soehnlein and Lindbom, 2010; 
Weber and Noels, 2011). These aggravate 
endothelial dysfunction, lure monocytes into the 
lesion, activate macrophages and promote foam 
cell formation and contribute to plaque 
destabilization, promote endothelial erosion and 
contribute to weakening of fibrous cap 
(Soehnlein, 2012; Doring et al., 2015; Federico 
et al., 2015). They promote plaque vulnerability 
by releasing gelatinases, collogenases, elastase 
and myeloperoxidase (Carbone et al., 2015). 
Proteolysis of the ECM mediated by neutrophil 
proteases promote atheroprogression and 
thrombus growth and plaque destabilization 
(Massberg et al., 2010; Hartwig et al., 2015; 
Pende et al., 2016). 
i. Mast cells: Mast cells are pro-inflammatory 
effector cells present in the human arterial intima 
and in evolving atherosclerotic lesions (Kovanen, 
2009; Galkina and Ley, 2009). They are actively 
involved in the initiation, progression and 
destabilization of atherosclerosis by inducing 
atherogenic lipid profile and vascular 
inflammation (Bot et al., 2007; Sun et al., 2007; 
Tang et al., 2009; Heikkila et al., 2010; Smith et 
al., 2012). They produce interleukin (IL) – 6; and 
interferon (IFN) – Y which promote 
atherogenesis by augmenting the expression of 
matrix – degrading proteins and 
proinflammatory cytokines. Other mast cell – 
specific proteases such as chymase, tryptase, 
cathepsin, heparin and growth factors, histamine 
and chemokines play different roles in 
atherogenesis including matrix degradation, 
apoptosis and enhanced recruitment of 
inflammatory cells (Sun et al., 2007; Bot and 
Biesen 2011; Spinas et al., 2014; Wezel et al., 
2015; Bot et al., 2015) indirectly influencing 
activity of other cells of immune system,  
modulating proliferation and apoptosis of 
endothelial and VSMC (Czyzewska – Buczynska 
and Witkiewicz, 2011) 
Some of the factors such as f-GF and histamine 
activate SMC surface receptors and accelerate 
their migration and proliferation. The elevation 
of the cytokines/chemokines may contribute to 
leulocyte adhesion and migration, foam cell 
formation and SMC apoptosis (Pfeniger et al., 
2013). In addition, mast cells participate in lipid 
retention and vascular cell remodeling and are 
mediators of innate and adaptive immunity 
during atherosclerosis (Spinas et al., 2014; 
Wezel et al., 2015).  
j. Fibroblasts: Fibroblasts, when activated in 
response to injury, stretch, cytokines and 
hormones, release reactive oxygen species 
which stimulate cellular differentiation, 
migration, proliferation and collagen synthesis. 
Further, fibroblast NAD(P)H oxidase plays a 
direct role in neointimal hyperplasia as well as a 
paracrine role in vascular smooth muscle 
hypertrophy (Haurrani and Pagano, 2007). 
Fibroblasts also express several proinflammatory 
cytokines such as chemoattractant protein – 1 







(MCP - 1); 1L – 6, protein and mRNA (Xu et al., 
2007). During early stages of vascular insult, 
fibroblasts proliferate and migrate to the media 
and intima and effect inflammatory response by 
increasing production of ROS and release of 
various proinflammatory cytokines, growth 
factors, matrix metalloproteinases which 
synergistically initiate neointima formation 
followed by subsequent atherosclerosis (Liu and 
Kong, 2010). The MCP – 1 recruits monocytes 
which further activate fibroblast proliferation, 
adventitial thickening and additional cytokine 
production. The fibroblast monocyte 
amplification loop mediates adventitial 
inflammation in atherosclerosis (Tieu et al., 
2011). 
k. Vascular stem cells: These are 
undifferentiated oligopotent progenitor cells 
from blood, bone marrow or tunica adventitia 
which are capable of giving rise to mature 
functional cells in the vascular wall including 
endothelial and smooth muscle cells (Geng et al., 
2006). They contribute to atherosclerosis by 
migrating into the intima and differentiating into 
“abnormal” proliferative smooth muscle cells 
(Geng et al., 2006; Margariti et al., 2006; Tang 
et al., 2012; Bobryshev et al., 2012). When 
exposed to risk factors, multipotent vascular 
stem cells become proliferative and differentiate 
into VSMC that contribute to neointimal 
hyperplasia and hence atherogenesis (Tang et 
al., 2012). The vascular resident stem cells are 
also capable of differentiating into 
myofibroblasts that subsequently migrate to 
intima and contribute to neointimal hyperplasisa, 
vascular smooth muscle cells and endothelial 
cells that contribute to atherosclerosis (Kawabe 
and Hasebe, 2014). 
l. Pericytes: Pericytes, also called Rouget or 
perivascular cells, constitute a pool of branched 
or stellate cells located around and sharing a 
basement membrane with endothelial cells in the 
heart, large and small vessels. They are located 
in the subendothelial zone and in the tunica 
adventitia (Diaz – Flores, 2009; Volz et al., 
2015). They are usually involved in maintenance 
of vascular contractility, permeability, control of 
vascular pressure, angiogenesis, immune 
defence, production of extracellular matrix and 
keeping stability of the vessels (Diaz – Flores, 
2009; Armulik et al., 2011). They are pluripotent 
and can give rise to various cells including 
macrophages and myofibroblasts (Dulmovits and 
Herman, 2012). 
These cells have been implicated in all stages of 
atherosclerosis from initiation and progression to 
complication (Orekhov et al., 2014; Orekhov et 
al., 2015) by various mechanisms: For example 
they may produce signaling molecules which 
attract and recruit inflammatory cells or be 
involved in lipid accumulation and formation of 
foam cells (Ivanova et al., 2015); promote 
growth and vascularization of the atherosclerotic 
plaque; participate in local inflammatory process 
and thrombosis (Ivanova and Orekhov, 2016). 
Some studies have even provided evidence that 
it is the pericyte – like cells rather than SMC and 
other cells which are the key cellular element 
promoting the formation of atherosclerotic 
lesions (Orekhov and Bobryshev, 2015). 
m. Red Blood Cells: Red blood cell (RBC) 
microvesicles enhance activation of vascular 
endothelium leading to vascular inflammation 
and atherogenesis (Blum, 2009). The cell 
membrane and haemoglobin of RBCs are both 
atherogenic. The cholesterol component of the 
membrane contributes to lipid deposition and 
lipid core expansion upon intraplaque 
hemorrhage. Cell – free haemoglobin is prone to 
oxidation and the oxidation products possess 
proxidant and proinflammatory activities (Jeney 
et al., 2014). Cross talk between RBC and 
immune cells contributes to progression of 
atherosclerosis. In particular, oxidized, 
senescent or stored RBC due to surface antigen 
modification and release of pro- oxidant and pro 
inflammatory molecules impair innate and 
adaptive immune response. Further, stored RBC 
accompanied by shredding of extracellular 
vesicles stimulate blood mononuclear cells and 
macrophages to release proinflammatory 
cytokines (Buttari et al., 2015). 
 
In conclusion atherogenesis involves all the cells 
in the vessel wall and in blood. These cells 
interact synergistically with each other through 







various chemical signals which influence 
proliferation migration and secretory activity. 
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